Laboratory findings among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
- "At the time of TCZ administration, all patients presented lymphopenia (below 1 × 10^3 cells/uL) and high levels of inflammatory markers, including CRP, fibrinogen, ferritin and IL-6. Ten days after, the lymphocyte count increased, especially in improved patients. CRP, fibrinogen and ferritin levels decreased toward the range of normality, while D-Dimer and IL-6 levels increased both in improved and worsened patients"
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Outcomes among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Patient characteristics among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Laboratory findings among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Methods for tracking outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Discussion from "Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy"